These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26629467)

  • 1. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.
    Kılıç N; Özdemir Ö; Başar HC; Demircan F; Ekmez F; Yücel O
    Avicenna J Med; 2015; 5(4):123-7. PubMed ID: 26629467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
    Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.
    Shaltout A; Shohyab A; Youssef MA
    Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):254-8. PubMed ID: 22948132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    D'Angelo A; Amso NN; Hassan R
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
    Bassiouny YA; Dakhly DMR; Bayoumi YA; Salaheldin NM; Gouda HM; Hassan AA
    Int J Gynaecol Obstet; 2018 Feb; 140(2):217-222. PubMed ID: 29055130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
    Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.
    Torabizadeh A; Vahidroodsari F; Ghorbanpour Z
    Iran J Reprod Med; 2013 Oct; 11(10):837-42. PubMed ID: 24639705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
    Carizza C; Abdelmassih V; Abdelmassih S; Ravizzini P; Salgueiro L; Salgueiro PT; Jine LT; Nagy P; Abdelmassih R
    Reprod Biomed Online; 2008 Dec; 17(6):751-5. PubMed ID: 19079957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
    Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection.
    Taheripanah R; Vasef M; Zamaniyan M; Taheripanah A
    Int J Fertil Steril; 2018 Apr; 12(1):1-5. PubMed ID: 29334199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
    Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
    Youssef MA; Abou-Setta AM; Lam WS
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003719. PubMed ID: 27106604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome.
    Youssef MA; Al-Inany HG; Evers JL; Aboulghar M
    Cochrane Database Syst Rev; 2011 Feb; (2):CD001302. PubMed ID: 21328249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assisted reproductive technologies for male subfertility.
    Cissen M; Bensdorp A; Cohlen BJ; Repping S; de Bruin JP; van Wely M
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD000360. PubMed ID: 26915339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.